Neos Therapeutics (NEOS): Thoughts After Management Meetings - BMO

September 20, 2016 9:44 AM EDT
Get Alerts NEOS Hot Sheet
Price: $6.52 --0%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 5 | New: 60
Trade NEOS Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

BMO Capital analyst, Gary Nachtman, reiterated his Outperform rating on shares of Neos Therapeutics (NASDAQ: NEOS) after meeting with management. The analyst remains positive on the Rx ramp for Adzenys XR-ODT, as well as the potential approvals/launches of Cotempla XRODT and NT-0201 in 2H17 that would improve operating leverage. Coverage for Adzenys XR-ODT has been progressing well, but gross-to-nets will continue to be a headwind for some time.

No change to the price target of $15.

For an analyst ratings summary and ratings history on Neos Therapeutics click here. For more ratings news on Neos Therapeutics click here.

Shares of Neos Therapeutics closed at $7.55 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

BMO Capital

Add Your Comment